Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

(marketscreener.com) NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodiesSAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer Annual...https://www.marketscreener.com/quote/stock/NEKTAR-THERAPEUTICS-45013433/news/Nektar-Therapeutics-Presents-Preclinical-Data-from-Novel-PEGylated-Interferon-Gamma-Program-NKTR-28-42271663/?utm_medium=RSS&utm_content=20221110